Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ruxolitinib Topical Cream
Ruxolitinib · 1 trial · 1 indication
Change in Cutaneous Dermatomyositis Activity and Severity Index (CDASI) activity score (range 0 - 100; higher scores indicate greater disease activity) at 8 weeks
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | 1.5 % Ruxolitinib cream |
| Name | Type | Description |
|---|---|---|
| Ruxolitinib Topical Cream | DRUG | 1.5% cream |
Inclusion Criteria: * Patients 18 years and older with refractory cutaneous symptoms related to either classic dermatomyositis (CD), juvenile dermatomyositis (JD), or amyopathic dermatomyositis (AD). Diagnosis will be based on either Bohan and Peter criteria (CD and JD) or Sontheimer's criteria (AD...
Ruxolitinib is being studied as a topical cream for refractory cutaneous dermatomyositis, a skin condition associated with the autoimmune disease dermatomyositis. It is currently in Phase 2 clinical development and is not yet approved for this use.
Ruxolitinib is a small molecule that belongs to the -tinib class of kinase inhibitors. It works by inhibiting certain kinase enzymes involved in inflammatory signaling pathways, which are thought to contribute to the skin manifestations of dermatomyositis.
Ruxolitinib is being developed by Community Health Systems, Inc., which trades under the ticker CYH. The company is conducting a Phase 2 clinical trial to evaluate the topical cream formulation for dermatomyositis.
Ruxolitinib is in Phase 2 clinical development for dermatomyositis. It is an investigational drug and has not been approved by the FDA for this indication. The ongoing trial is recruiting participants in the United States.
Ruxolitinib is being evaluated in a Phase 2 clinical trial with the identifier NCT06857240, titled 'Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis.' The trial is recruiting 15 participants aged 18 years and older in the United States.
Yes, Ruxolitinib Topical Cream is the formulation being studied in the current clinical trial. The drug is referred to as Ruxolitinib, and the topical cream is the specific dosage form under investigation for dermatomyositis.